363 completed, 80 unknown, 35 terminated, 27 withdrawn. 174 Phase 2, 141 Phase 3, 99 Phase 4, 95 Phase 1, 41 Not applicable.
Follow Ranibizumab: new trials by email Literature Review of Ranibizumab trials Research Report on Ranibizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-05) OLN324, Ranibizumab - Wet Age-related Macular Degeneration | Phase 3 | Not yet recruiting | Ollin Biosciences, Inc. | 400 | 2026-10-15 | 2026-09-11 |
| Continuous Delivery of Ranibizumab Via the Port Delivery System for Proliferative Diabetic Retinopathy-related Vitreous Hemorrhage With Pars Plana Vitrectomy and Limited PRP. PDS Implant filled with 100 mg/mL Ranibizumab, Ranibizumab - Proliferative Diabetic Retinopathy, Diabetic Retinopathy | Phase 4 | Not yet recruiting | Southeast Retina Center, Georgia | 20 | 2026-09-01 | 2026-10-13 |
| A Clinical Trial Evaluating the Efficacy and Safety of Sanhuang Jingshiming Pills in the Treatment of nAMD Sanhuang Jingshiming/Pills placebo - AMD | Phase 3 | Not yet recruiting | Tasly Pharmaceutical Group Co., Ltd | 450 | 2026-04-30 | 2026-04-08 |
| A Study to Evaluate the Usability of the SB11 PFS in Trial Participants With Wet AMD, Macular Oedema Secondary to RVO, or mCNV SB11 PFS - Age-Related Macular Degeneration, Branch Retinal Vein Occlusion With Macular Edema | Phase 2 | Completed | Samsung Bioepis Co., Ltd. | 30 | 2026-03-30 | 2026-04-24 |
| A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD Susvimo PDS Implant, Ranibizumab - Neovascular Age-related Macular Degeneration | Phase 3 | Recruiting | Hoffmann-La Roche | 250 | 2025-11-27 | 2026-10-15 |
| Incidence of Hypoxia During Intravitreal Anti-VEGF (Vascular Endothelial Growth Factor) Injections for Retinopathy of Prematurity (ROP) Under Topical Anesthesia ranibizumab - Retinopathy of Prematurity | Recruiting | Minia University | 74 | 2025-10-01 | 2026-07-14 | |
| Identification of Molecular Signals in Vitreous Humor Associated With Suboptimal Response to Vascular Endothelial Growth Factor (VEGF) Inhibition in Neovascular Age-related Macular Degeneration (nAMD) Within a Clinical Trial Setting Faricimab, Ranibizumab - Age Related Macular Degeneration | Not applicable | Recruiting | Singapore National Eye Centre | 117 | 2025-07-18 | 2026-09-16 |
| A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME Remigromig, Ranibizumab - Diabetic Macular Edema (DME) | Phase 2 / Phase 3 | Active not recruiting | EyeBiotech Ltd. | 1054 | 2025-04-16 | 2026-10-15 |
| Outcomes of Intravitreal Ranibizumab Injection for Diabetic Vitreous Hemorrhage Ranibizumab - Diabetic Vitreous Hemorrhage, Intravitreal Injections | Phase 4 | Completed | Benha University | 30 | 2025-04-01 | 2026-07-08 |
| Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Diabetic Macular Edema BAT5906 injection, Lucentis - Diabetic Macular Edema (DME) | Phase 3 | Recruiting | Bio-Thera Solutions | 406 | 2024-10-09 | 2026-04-07 |
| A Study to Evaluate the Efficacy and Safety of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME Ranibizumab, Remigromig - Diabetic Macular Edema (DME) | Phase 2 / Phase 3 | Active not recruiting | EyeBiotech Ltd. | 984 | 2024-08-07 | 2026-10-14 |
| A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD) PDS With Ranibizumab (100 mg/mL), Ranibizumab (10 mg/mL) - Neovascular Age-related Macular Degeneration, nAMD | Phase 3 | Active not recruiting | Hoffmann-La Roche | 68 | 2024-06-17 | 2026-09-01 |
| A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema Ranibizumab 10mg/ml Injection, Lucentis - Diabetic Macular Edema, Diabetic Retinopathy | Phase 3 | Completed | Incepta Pharmaceuticals Ltd | 70 | 2024-03-30 | 2026-09-25 |
| A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia Faricimab, Ranibizumab, Sham Procedure - Choroidal Neovascularization Secondary to Pathologic Myopia | Phase 3 | Completed | Hoffmann-La Roche | 280 | 2024-03-06 | 2026-07-31 |
| A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) bevacizumab, ranibizumab - Neovascular Age-related Macular Degeneration, Age-Related Macular Degeneration | Phase 3 | Completed | Outlook Therapeutics, Inc. | 400 | 2024-01-24 | 2026-07-23 |
| A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration Ranibizumab, Aflibercept, Port Delivery System with ranibizumab (PDS) - Neovascular Age-Related Macular Degeneration | Phase 3 | Withdrawn | Hoffmann-La Roche | 2023-12-29 | 2024-01-18 | |
| Relationship Between Dyslipidemia and The Response of Diabetic Macular Edema to Intravitreal Injection of Anti Vascular Endothelial Growth Factor Agents Ranibizumab Injection [Lucentis], Aflibercept Injection [Eylea] - Diabetic Macular Edema | Early Phase 1 | Unknown | Sohag University | 50 | 2023-12-12 | 2024-01-16 |
| A Study to Evaluate the Usability of the SB11 PFS in Subjects With Wet AMD or Macular Oedema Secondary to RVO SB11 PFS - Neovascular Age-related Macular Degeneration, Macular Edema | Phase 2 | Completed | Samsung Bioepis Co., Ltd. | 34 | 2023-11-21 | 2024-12-30 |
| Ultra-wide-field Fluorescein Angiography in Patients With Macular Edema Secondary to Retinal Vein Occlusion Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS], Ultra-wide Fluorescein Angiography - Retinal Vein Occlusion, Macular Edema | Unknown | Renmin Hospital of Wuhan University | 60 | 2023-10-09 | 2023-10-18 | |
| Laser Photocoagulation and Ranibizumab Treatment in Proliferative Diabetic Retinopathy Ranibizumab 0.5 mg, laser photocoagulation (PRP) - Proliferative Diabetic Retinopathy (PDR) | Not applicable | Completed | Aswan University | 80 | 2023-07-01 | 2026-09-15 |
Showing 20 of 526. Sign in to see all of them.
Macular Degeneration (182) · Macular Edema (78) · Retinal Vein Occlusion (60) · Choroidal Neovascularization (57) · Diabetic Retinopathy (38) · Vision Disorders (25) · Wet Macular Degeneration (25) · Retinal Diseases (22) · Diabetes Mellitus (20) · Polypoidal Choroidal Vasculopathy (15) · Eye Diseases (13) · Edema (11) · Neovascularization, Pathologic (10) · Retinopathy of Prematurity (10) · Glaucoma, Neovascular (8)
Novartis Pharmaceuticals (53) · Hoffmann-La Roche (18) · Genentech, Inc. (17) · Allergan (13) · Novartis (13) · National Eye Institute (NEI) (7) · Alcon Research (6) · California Retina Consultants (6) · Johns Hopkins University (6) · Ophthotech Corporation (6) · Sun Yat-sen University (6) · Vitreous -Retina- Macula Consultants of New York (6) · Bayer (5) · Instituto de Olhos de Goiania (5) · Jaeb Center for Health Research (5)
United States (224) · Germany (66) · United Kingdom (52) · China (50) · Italy (41) · Spain (41) · France (40) · South Korea (38) · Canada (37) · Hungary (35) · Australia (34) · Switzerland (32) · Austria (30) · Poland (30) · Czechia (28)
David M Brown, MD (3) · Gilda Cennamo (3) · Richard F. Spaide, M.D. (3) · Salvatore Grisanti, M.D. Prof. (3) · Anne Fung, MD (2) · Avner Ingerman, MD (2) · Charles C Wykoff, PhD, MD (2) · Charles Miller, MD PhD (2)
PMID 32374423, PMID 30957581, PMID 34934034, PMID 36774994, PMID 17021318, PMID 17021319, PMID 25148789, PMID 26584450, PMID 37260074, PMID 37585454, PMID 39154860, PMID 39209113, PMID 19255158, PMID 19726427, PMID 20008710, PMID 20189654, PMID 20378094, PMID 20417925, PMID 20427088, PMID 20683380, PMID 20920825, PMID 21571677, PMID 21794843, PMID 22426346, PMID 22965590, PMID 22999634, PMID 23009891, PMID 23352196, PMID 23361508, PMID 23415775, PMID 23453513, PMID 23699977, PMID 23706949, PMID 23745581, PMID 24768239, PMID 25102193, PMID 25439429, PMID 25439614, PMID 26050541, PMID 26452713, PMID 26802783, PMID 26992841, PMID 27234930, PMID 29752001, PMID 30293228, PMID 30419298, PMID 31047350, PMID 31047503, PMID 31668888, PMID 31826853
2014 (7), 2009 (5), 2023 (3), U10EY014231 (3), U10EY018817 (3), 2017 (2), 2025 (2), U10EY014229 (2), 2018 (1), 2019 (1), U10EY017823 (1), U10EY024527 (1)